Physicians require a screening instrument to detect psychiatric disorders in patients with chronic fatigue syndrome (CFS). Different threshold scores on the Hospital Anxiety and Depression scale (HAD) and the mental health scale of the Medical Outcome Survey (MOS) were compared with two gold standards for the presence or absence of psychiatric disorder, standard diagnostic criteria (DSM-111-R) and a threshold score for the number of psychiatric symptoms at a standardized psychiatric interview (Revised Clinical Interview Schedule total cut-off score of 11/12). They were compared by use of validating coefficients and receiver operating characteristics in 136 consecutive CFS medical outpatients.
INTRODUCTION
Around one half of chronic fatigue syndrome (CFS) patients attending medical outpatients clinics have psychiatric disorders, usually depression or anxietyl. Most patients with CFS referred to hospital will be seen by physicians who have no specific training in the detection of psychiatric disorder. There is a need for a valid self-rated screening questionnaire that physicians can use with CFS patients2. Unfortunately, two commonly used psychiatric screening instruments have proved invalid in British CFS patients3.
In the current study, we have examined the validity of two other self-rated screening instruments, the 14-item Hospital Anxiety and Depression rating scale (HAD)4 and the mental health scale of the Medical Outcome Survey short form (MOS)5. The HAD scale was designed to detect depression and anxiety in medical and surgical outpatients using a cut-off score of 8-10 on either the anxiety or the depression scales4. The MOS, a shortened version of the SF-366, is a widely used multidimensional measure of function and the mental health scale of the SF-36 has proved an efficient screening instrument for detecting psychiatric morbidity in general practice7. The physical function scale of the MOS is a sensitive measure of clinical improvement in physical function among CFS patients8. If the 5-item 'Department of Psychiatry, University of Manchester, and Guild NHS Trust, Royal Preston Hospital, Preston PR2 4HT; 2Department of Clinical Psychology, MOS mental health scale proved to be a valid measure for detecting anxiety and depression in CFS patients, it could be recommended as a quick multidimensional measure of function for use in clinical practice.
METHODS
Patients with CFS over the age of 18 years were recruited from consecutive referrals to a university department of medicine outpatient clinic from consultant physicians and general practitioners across North-West England and North Wales. Patients were directly recruited from the medical clinic and were not referred to a psychiatric department before entering the study. All patients were medically assessed by a doctor under the direct supervision of a consultant physician. A full history was taken; they were physically examined; and laboratory investigations (full blood count, erythrocyte sedimentation rate, routine biochemistry, creatine phosphokinase, C-reactive protein and immunological screen including thyroid antibodies) were carried out.
Inclusion criteria specified that patients had to meet operationalized 'Oxford' research criteria for chronic fatigue syndrome9: (a) a principal complaint of fatigue, exacerbated by physical activity (and usually mental activity), of six months' duration; (b) impairment in three out of four areas of activity (activities of daily living, occupational, social and leisure activities); (c) absence of medically significant cause of fatigue, verified by a consultant physician: (d) absence of schizophrenia, bipolar disorder, eating disorder, or alcohol or illicit drug abuse, verified by a consultant or senior registrar in psychiatry.
Exclusion criteria were a history of ischaemic heart disease, presence of suicidal ideation, and inability to read and write English. No other inclusion or exclusion criteria were employed. All patients met the revised Centers for Disease Control criteria for CFS10. They were participating in a treatment trial of graded exercise and fluoxetine but the assessments reported in this paper were made before treatment started. Patients gave written informed consent to participation in the trial and ethics committee approval was obtained.
The validity of the HAD and MOS mental health scales was examined in two ways. The first was by comparison with a standardized psychiatric interview of known validity and reliability, conducted by a psychologist using the revised Clinical Interview Schedule (CIS-R)1 A cut-off score of 11/12 was used to designate psychiatric caseness. The second method was comparison with standardized criteria for a psychiatric diagnosis (DSM-III-R)12, excluding the sections on somatoform disorders (which would technically include all CFS patients by definition) and sleep disorders (which are common in CFS in the absence of psychiatric disorder1 3). The psychologist determined whether the CFS patients met these criteria by asking supplementary questions.
The patients also completed the HAD scale. The highest score on either the depression or the anxiety scale was used to designate a possible case of anxiety and/or depression. We tested the recommended cut-off scores on the range 7/8 to 10/1 1. Higher scores indicate a greater likelihood of psychiatric disorder. The MOS mental health scale was also administered and the recommended cut-off score of 67/68 was used to detect possible cases of poor mental health function, together with lower scores of 59/60 or 63/64 to increase the positive predictive value (lower scores indicate a greater likelihood of psychiatric disorder). Patients had all the assessments on the same day and the interviews were performed blind to the HAD and MOS mental health questionnaire scores.
The highest score on either the HAD anxiety or depression scales and on the MOS mental health score was compared with each of the gold standard measures. Receiver operating characteristics (ROC) were analysed from the area under the curve (AUC) by Wilcoxon's test approach3'14. An AUC of 0.80 or higher is a good indicator that a screening instrument is valid and efficient in a particular population15. RESULTS 227 patients were assessed for the treatment trial, and 62 did not fulfil criteria for CFS. Of the remaining 165, 25 did not consent to the treatment trial, 3 could not stop antidepressants because of suicide risk and one required other medical treatment first. The remaining 136 CFS patients (82% of consecutive CFS patients attending medical outpatients) who started the treatment trial constitute the sample reported in this paper (data obtained before they started their treatment). The mean (SD) age of the total sample was 39 (11) years, median (interquartile range) duration of CFS symptoms was 28 (40) months and median (interquartile range) education was 1 1 (1) years. 97 (71%) patients were female; 83 (61%) were married or cohabiting and 29 (21%) were currently in paid employment. 62 patients (46%) met DSM-III-R criteria for a psychiatric disorder: 14 (10%) had major depression, 32 (24%) had either dysthymia or depressive disorder not otherwise specified, 14 (10%) had various anxiety disorders and 2 (2%) had somatization disorder. All patients completed the HAD and MOS scales and none refused the psychiatric interview. Table 1 shows validity coefficients and the AUC for the highest score on the HAD anxiety or depression scale at cut-off scores of from 7/8 to 10/11 against the two gold standards for measurement of psychiatric disorder. A cutoff score of 9/10 on either the anxiety or depression scales of the HAD scales was a valid and efficient measure of psychiatric disorder, with high sensitivity, specificity and positive predictive value and a low overall misclassification rate. Table 2 shows validity coefficients and the AUC for the MOS mental health scale at cut-off scores 59/60, 63/64 and 67/68. The AUC was below 0.80 at all cut-off points. The usual cut-off point of 67/68 was the most satisfactory in terms of AUC but the specificity was low and the misclassification rate was high; this screening instrument will tend to detect psychiatric disorder when none is present.
DISCUSSION
As judged by Goldberg and Williams' criteria for screening instruments15, the HAD scales with a cut-off score of 9/10 seem to be valid and efficient tools for detecting depression and anxiety in CFS patients (as they are in other medical conditions16). Treatment trial data in the same sample of CFS patients17 suggest that the HAD depression scale is sensitive to change in response to antidepressant treatment; thus it could serve non-psychiatrists not only as a screening method but also as an instrument for monitoring the success or failure of antidepressant treatment. The scales are quickly completed and their content was acceptable to the CFS patients in this series. By contrast, the MOS mental health scale appears to lack validity and specificity at its usual cut-off score of 67/68. Since the MOS mental health scale was also not sensitive to change in our treatment trial17, we cannot recommend it either for psychiatric screening or for monitoring treatment of psychiatric disorder.
There are some methodological issues to be raised. The patients in this study were participants in a randomized controlled trial of treatment and the results may not apply to CFS patients who are unwilling to participate in such trials. However, participants in our study did not differ from non-participants in age, gender, or demographic or clinical characteristics; nor were they obviously different from participants in other British treatment trials8'18 or CFS patients attending medical outpatient clinics19. Over 80% of consecutive patients attending a medical outpatient clinic were recruited into this study. The sample size of 136 patients is larger than that in the previous British study attempting to validate psychiatric screening instruments in CFS3 but small compared with some validation studies of the HAD16, MOSS or other psychiatric screening instruments15.
The main semistructured psychiatric interview was the CIS-R, and we used this for three reasons. First, it was appropriate for a trained psychologist who had not used any semistructured psychiatric interview before11; second, it is designed not to be overtly psychiatric in content (unlike most other semistructured psychiatric inter-views1 1); third, it generated another validated gold standard for assessing psychiatric morbidity (total CIS-R score) in a group of patients who may be reluctant to disclose symptoms of anxiety and depression. A disadvantage of the CIS-R is that, unlike other semistructured psychiatric interviews, it does not directly generate DSM-lII-R criteria. There was a high proportion of patients with depressive disorder not otherwise specified who admitted to four symptoms of depressive disorder rather than five and so would have met ICD-10 criteria for mild depressive disorder20 but not DSM-III-R major depression. The low prevalence of dysthymia and major depression may reflect the absence of patients with very longstanding CFS and the fact that many CFS patients with or without depression had been treated with antidepressants before referral.
There was no control group with which to compare the performance of the HAD and MOS mental health scales. However, in other medical outpatient and primary care settings both the HAD and MOS mental health scales perform satisfactorily5'7'16. The prevalence of psychiatric disorder in CFS patients found in general practice may be higher than in medical outpatients21. Both the MOS mental health scale and the HAD may detect a greater proportion of true-positive to false-positive cases of psychiatric disorder among CFS patients in general practice22. The MOS mental health scale might be a more satisfactory psychiatric screening tool among CFS patients in general practice than in medical outpatients.
There are three probable reasons why we obtained better results with the HAD than those in a previous validity study3 of the General Health Questionnaire (GHQ) and
Beck Depression Inventory (BDI) as screening tools for the detection of psychiatric morbidity in CFS patients. First, both our psychiatric screening questionnaires and our psychiatric interview are specifically designed to be acceptable to non-psychiatric patients, unlike the BDI, which is unacceptable to CFS patients in our clinical experience; second, the BDI was completed two weeks after the psychiatric interview and so the mental state may have changed; third, the GHQ is insensitive to the detection of longstanding mental health problems because it asks only about recent changes from usual (the GHQ can be adapted to deal with this drawback)22.
